Base de dados : MEDLINE
Pesquisa : D03.633.300.046.250.450 [Categoria DeCS]
Referências encontradas : 187 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 19 ir para página                         

  1 / 187 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28632878
[Au] Autor:De Filippo E; Manga P; Schiedel AC
[Ad] Endereço:Pharmaceutical Chemistry I, PharmaCenter Bonn, University of Bonn, Bonn, Germany.
[Ti] Título:Identification of Novel G Protein-Coupled Receptor 143 Ligands as Pharmacologic Tools for Investigating X-Linked Ocular Albinism.
[So] Source:Invest Ophthalmol Vis Sci;58(7):3118-3126, 2017 Jun 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: GPR143 regulates melanosome biogenesis and organelle size in pigment cells. The mechanisms underlying receptor function remain unclear. G protein-coupled receptors (GPCRs) are excellent pharmacologic targets; thus, we developed and applied a screening approach to identify potential GPR143 ligands and chemical modulators. Methods: GPR143 interacts with ß-arrestin; we therefore established a ß-arrestin recruitment assay to screen for compounds that modulate activity. Because GPR143 is localized intracellularly, screening with the wild-type receptor would be restricted to agents absorbed by the cell. For the screen we used a mutant receptor, which shows similar basal activity as the wild type but traffics to the plasma membrane. We tested two compound libraries and investigated validated hits for their effects on melanocyte pigmentation. Results: GPR143, which showed high constitutive activity in the ß-arrestin assay, was inhibited by several compounds. The three validated inhibitors (pimozide, niclosamide, and ethacridine lactate) were assessed for impact on melanocytes. Pigmentation and expression of tyrosinase, a key melanogenic enzyme, were reduced by all compounds. Because GPR143 appears to be constitutively active, these compounds may turn off its activity. Conclusions: X-linked ocular albinism type I, characterized by developmental eye defects, results from GPR143 mutations. Identifying pharmacologic agents that modulate GPR143 activity will contribute significantly to our understanding of its function and provide novel tools with which to study GPCRs in melanocytes and retinal pigment epithelium. Pimozide, one of three GPR143 inhibitors identified in this study, maybe be a good lead structure for development of more potent compounds and provide a platform for design of novel therapeutic agents.
[Mh] Termos MeSH primário: Albinismo Ocular/genética
Proteínas do Olho/genética
Doenças Genéticas Ligadas ao Cromossomo X/genética
Glicoproteínas de Membrana/genética
Mutação
RNA/genética
[Mh] Termos MeSH secundário: Albinismo Ocular/tratamento farmacológico
Albinismo Ocular/metabolismo
Células Cultivadas
Análise Mutacional de DNA
Etacridina/farmacologia
Éxons
Proteínas do Olho/antagonistas & inibidores
Proteínas do Olho/metabolismo
Doenças Genéticas Ligadas ao Cromossomo X/dietoterapia
Doenças Genéticas Ligadas ao Cromossomo X/metabolismo
Seres Humanos
Ligantes
Glicoproteínas de Membrana/antagonistas & inibidores
Glicoproteínas de Membrana/metabolismo
Niclosamida/farmacologia
Linhagem
Pimozida/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Eye Proteins); 0 (GPR143 protein, human); 0 (Ligands); 0 (Membrane Glycoproteins); 1HIZ4DL86F (Pimozide); 63231-63-0 (RNA); 8KK8CQ2K8G (Niclosamide); WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.16-21128


  2 / 187 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27658386
[Au] Autor:Chen C; Lin F; Wang X; Jiang Y; Wu S
[Ad] Endereço:Department of Obstetrics and Gynecology, Shanghai General Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No. 650, Xinsongjiang Road, Songjiang District, Shanghai, 200080, China.
[Ti] Título:Mifepristone combined with ethacridine lactate for the second-trimester pregnancy termination in women with placenta previa and/or prior cesarean deliveries.
[So] Source:Arch Gynecol Obstet;295(1):119-124, 2017 Jan.
[Is] ISSN:1432-0711
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: This study was aimed to evaluate the safety and efficacy of the second-trimester medical abortions using mifepristone and ethacridine lactate in women with placenta previa and/or prior cesarean deliveries. METHODS: The patients who underwent a second-trimester pregnancy termination from January 2009 to December 2015 were retrospectively analyzed. The eligible patients were assigned to four groups based on placentation and cesarean history. The abortion interval (AI), blood loss, hospital stays, incidence of curettage, and transfusion were reviewed. RESULTS: Two women underwent cesarean sections for placenta increta. Finally, 443 patients were enrolled in this study, including 92 with placenta previa, 153 with prior cesarean deliveries, 36 with the both factors, and 236 with normal placentation and no cesarean delivery history. All the included cases had a successful vaginal delivery. There was no significant difference in AI, hospital stay, rate of hemorrhage, and transfusion among the four groups. Patients with prior cesarean section had higher blood loss than the normal group (P = 0.0017), as well as patients with both placenta previa and prior cesarean (P = 0.0018). However, there was no obvious blood loss in patients with placenta previa when compared with normal placetal patients (P = 0.23). No uterine rupture occurred in all patients. CONCLUSIONS: Mifepristone combined with ethacridine lactate is safe and effective for patients with low placentation or/and prior cesarean in the second-trimester pregnancy termination.
[Mh] Termos MeSH primário: Aborto Induzido/métodos
Cesárea/métodos
Etacridina/uso terapêutico
Mifepristona/uso terapêutico
Placenta Prévia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Etacridina/administração & dosagem
Etacridina/farmacologia
Feminino
Seres Humanos
Mifepristona/administração & dosagem
Gravidez
Segundo Trimestre da Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
320T6RNW1F (Mifepristone); WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160924
[St] Status:MEDLINE
[do] DOI:10.1007/s00404-016-4205-8


  3 / 187 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26624983
[Au] Autor:Rotin LE; Gronda M; MacLean N; Hurren R; Wang X; Lin FH; Wrana J; Datti A; Barber DL; Minden MD; Slassi M; Schimmer AD
[Ad] Endereço:Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
[Ti] Título:Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
[So] Source:Oncotarget;7(3):2765-79, 2016 Jan 19.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Targeting Bruton's tyrosine kinase (BTK) with the small molecule BTK inhibitor ibrutinib has significantly improved patient outcomes in several B-cell malignancies, with minimal toxicity. Given the reported expression and constitutive activation of BTK in acute myeloid leukemia (AML) cells, there has been recent interest in investigating the anti-AML activity of ibrutinib. We noted that ibrutinib had limited single-agent toxicity in a panel of AML cell lines and primary AML samples, and therefore sought to identify ibrutinib-sensitizing drugs. Using a high-throughput combination chemical screen, we identified that the poly(ADP-ribose) glycohydrolase (PARG) inhibitor ethacridine lactate synergized with ibrutinib in TEX and OCI-AML2 leukemia cell lines. The combination of ibrutinib and ethacridine induced a synergistic increase in reactive oxygen species that was functionally important to explain the observed cell death. Interestingly, synergistic cytotoxicity of ibrutinib and ethacridine was independent of the inhibitory effect of ibrutinib against BTK, as knockdown of BTK did not sensitize TEX and OCI-AML2 cells to ethacridine treatment. Thus, our findings indicate that ibrutinib may have a BTK-independent role in AML and that PARG inhibitors may have utility as part of a combination therapy for this disease.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Etacridina/farmacologia
Glicosídeo Hidrolases/antagonistas & inibidores
Leucemia Mieloide Aguda/tratamento farmacológico
Inibidores de Proteínas Quinases/farmacologia
Proteínas Tirosina Quinases/genética
Pirazóis/farmacologia
Pirimidinas/farmacologia
[Mh] Termos MeSH secundário: Animais
Linhagem Celular Tumoral
Sinergismo Farmacológico
Quimioterapia Combinada
Seres Humanos
Taninos Hidrolisáveis/farmacologia
Células Jurkat
Camundongos
Camundongos SCID
Interferência de RNA
RNA Interferente Pequeno/genética
Espécies Reativas de Oxigênio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hydrolyzable Tannins); 0 (PCI 32765); 0 (Protein Kinase Inhibitors); 0 (Pyrazoles); 0 (Pyrimidines); 0 (RNA, Small Interfering); 0 (Reactive Oxygen Species); EC 2.7.10.1 (Agammaglobulinaemia tyrosine kinase); EC 2.7.10.1 (Protein-Tyrosine Kinases); EC 3.2.1.- (Glycoside Hydrolases); EC 3.2.1.143 (poly ADP-ribose glycohydrolase); WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151202
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.6409


  4 / 187 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25979969
[Au] Autor:Kawano S; Maruyama J; Nagashima S; Inami K; Qiu W; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Nishina H; Hata Y
[Ad] Endereço:Department of Medical Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8519, Japan;
[Ti] Título:A cell-based screening for TAZ activators identifies ethacridine, a widely used antiseptic and abortifacient, as a compound that promotes dephosphorylation of TAZ and inhibits adipogenesis in C3H10T1/2 cells.
[So] Source:J Biochem;158(5):413-23, 2015 Nov.
[Is] ISSN:1756-2651
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Transcriptional co-activator with PSD-95/Dlg-A/ZO-1 (PDZ)-binding motif (TAZ) regulates in cell proliferation and differentiation. In mesenchymal stem cells it promotes osteogenesis and myogenesis, and suppresses adipogenesis. TAZ activators are expected to prevent osteoporosis, obesity and muscle atrophy. TAZ activation induces epithelial-mesenchymal transition, confers stemness to cancer cells and leads to poor clinical prognosis in cancer patients. In this point of view, TAZ inhibitors should contribute to cancer therapy. Thus, TAZ attracts attention as a two-faced drug target. We screened for TAZ modulators by using human lung cancer A549 cells expressing the fluorescent reporter. Through this assay, we obtained TAZ activator candidates. We unexpectedly found that ethacridine, a widely used antiseptic and abortifacient, enhances the interaction of TAZ and protein phosphatases and increases unphosphorylated and nuclear TAZ. Ethacridine inhibits adipogenesis in mesenchymal C3H10T1/2 cells through the activation of TAZ. This finding suggests that ethacridine is a bona fide TAZ activator and supports that our assay is useful to discover TAZ activators.
[Mh] Termos MeSH primário: Adipogenia/efeitos dos fármacos
Fármacos Antiobesidade/farmacologia
Etacridina/farmacologia
Peptídeos e Proteínas de Sinalização Intracelular/agonistas
Células Mesenquimais Estromais/efeitos dos fármacos
Proteína Fosfatase 1/metabolismo
Proteína Fosfatase 2/metabolismo
[Mh] Termos MeSH secundário: Transporte Ativo do Núcleo Celular/efeitos dos fármacos
Proteínas Adaptadoras de Transdução de Sinal/agonistas
Proteínas Adaptadoras de Transdução de Sinal/genética
Proteínas Adaptadoras de Transdução de Sinal/metabolismo
Linhagem Celular Tumoral
Avaliação Pré-Clínica de Medicamentos
Genes Reporter/efeitos dos fármacos
Células HEK293
Seres Humanos
Peptídeos e Proteínas de Sinalização Intracelular/antagonistas & inibidores
Peptídeos e Proteínas de Sinalização Intracelular/genética
Peptídeos e Proteínas de Sinalização Intracelular/metabolismo
Proteínas Luminescentes/genética
Proteínas Luminescentes/metabolismo
Células Mesenquimais Estromais/citologia
Células Mesenquimais Estromais/metabolismo
Fosfoproteínas/agonistas
Fosfoproteínas/genética
Fosfoproteínas/metabolismo
Fosforilação/efeitos dos fármacos
Regiões Promotoras Genéticas/efeitos dos fármacos
Proteína Fosfatase 1/química
Proteína Fosfatase 1/genética
Proteína Fosfatase 2/química
Proteína Fosfatase 2/genética
Processamento de Proteína Pós-Traducional/efeitos dos fármacos
Proteínas Serina-Treonina Quinases/antagonistas & inibidores
Proteínas Serina-Treonina Quinases/genética
Proteínas Serina-Treonina Quinases/metabolismo
Interferência de RNA
Proteínas Recombinantes de Fusão/química
Proteínas Recombinantes de Fusão/metabolismo
Proteínas Supressoras de Tumor/antagonistas & inibidores
Proteínas Supressoras de Tumor/genética
Proteínas Supressoras de Tumor/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adaptor Proteins, Signal Transducing); 0 (Anti-Obesity Agents); 0 (Intracellular Signaling Peptides and Proteins); 0 (Luminescent Proteins); 0 (Phosphoproteins); 0 (Recombinant Fusion Proteins); 0 (Tumor Suppressor Proteins); 0 (WWTR1 protein, human); 0 (YAP1 (Yes-associated) protein, human); EC 2.7.1.- (LATS1 protein, human); EC 2.7.1.11 (LATS2 protein, human); EC 2.7.11.1 (Protein-Serine-Threonine Kinases); EC 3.1.3.16 (PPP1CA protein, human); EC 3.1.3.16 (PPP2CA protein, human); EC 3.1.3.16 (Protein Phosphatase 1); EC 3.1.3.16 (Protein Phosphatase 2); WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150517
[St] Status:MEDLINE
[do] DOI:10.1093/jb/mvv051


  5 / 187 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25673444
[Au] Autor:Peng P; Liu XY; Li L; Jin L; Chen WL
[Ti] Título:Clinical analyses of 66 cases of mid-trimester pregnancy termination in women with prior cesarean.
[So] Source:Chin Med J (Engl);128(4):450-4, 2015 Feb 20.
[Is] ISSN:0366-6999
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The rate of cesarean delivery has significantly increased in China in the last decade. Women with prior cesarean history tend to have a higher risk of uterine rupture during termination of the pregnancy in mid-trimester than those without such a history. The aim of our study was to evaluate the influences of the potential risk factors on uterine rupture in women with prior cesarean. METHODS: We conducted this retrospective study of women with prior cesarean section, who underwent mid-trimester pregnancy termination between January 2006 and December 2013 in Peking Union Medical College Hospital. The protocol was oral administration of mifepristone and misoprostol for the patients with the gestational ages below 16 weeks or intra-amniotic injection of ethacridine lactate (EL) for those with at least 16 weeks of gestational ages. The thickness of the lower uterine segment (LUS) was measured before the termination of pregnancy. Logistic regression was used to study the risk factors of uterine rupture. RESULTS: The total rate of successful abortion was 93.9% (62/66). Four patients failed in induction, and one of them received curettage, whereas the other three experienced uterine rupture (4.5%). The successful rates of abortion were 85.7% (30/35) for women treated with mifepristone-misoprostol and 86.1% (31/36) for those treated with EL. There was a significant difference in the mean LUS thickness between the uterine rupture group (3.0 ± 2.0 mm) and the nonrupture group (7.0 ± 3.0 mm) (P < 0.05). The LUS thickness of <3 mm was associated with uterine rupture during mid-trimester pregnancy termination in women with prior cesarean (odds ratio, 94.0; 95% confidence interval 4.2-2106.1) after adjusted maternal age, gestational age, interdelivery interval and prior cesarean section. Severe bleeding that required transfusion occurred in one case (1.5%). CONCLUSIONS: Both the mifepristone-misoprostol and the EL regimens were effective and safe for the termination of mid-trimester pregnancy in women with prior cesarean. A thinner LUS is associated with a relatively high risk of uterine rupture.
[Mh] Termos MeSH primário: Aborto Induzido/efeitos adversos
Aborto Induzido/métodos
Cesárea
[Mh] Termos MeSH secundário: Etacridina/uso terapêutico
Feminino
Seres Humanos
Mifepristona/uso terapêutico
Misoprostol/uso terapêutico
Gravidez
Trimestres da Gravidez
Estudos Retrospectivos
Ruptura Uterina/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0E43V0BB57 (Misoprostol); 320T6RNW1F (Mifepristone); WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150213
[St] Status:MEDLINE
[do] DOI:10.4103/0366-6999.151073


  6 / 187 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25673206
[Au] Autor:Li N; Wu P; Zhao J; Feng L; Qiao FY; Zeng WJ
[Ad] Endereço:Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China, w461357598@163.com.
[Ti] Título:Effectiveness and safety of double-balloon catheter versus intra-amniotic injection of ethacridine lactate for termination of second trimester pregnancy in patients with liver dysfunction.
[So] Source:J Huazhong Univ Sci Technolog Med Sci;35(1):129-34, 2015 Feb.
[Is] ISSN:1672-0733
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:Severe liver dysfunction in pregnancy (SLDP) is rare but serious complications with high mortality rate. This study compared the effectiveness and safety of double-balloon catheter versus intra-amniotic injection of ethacridine lactate for the termination of second trimester pregnancy in patients with SLD. A total of 55 patients with indications of labor induction were enrolled and analyzed by retrospective control analysis method. Twenty-three cases adopted Cook double balloon dilation as Cook group, and 32 cases received intra-amniotic injection of ethacridine lactate as EL group. The primary outcome was evaluated by successful abortion rate and the difference in the induction-to-abortion interval. Secondary outcomes included liver function recovery and the frequency of adverse events. Both Cook and EL regimens were effective, with successful abortion rate of 87.0% and 93.8%, respectively (P=0.639). The induction-to-delivery interval was similar between Cook group and EL group (38.1 ± 21.5 vs. 41.3 ± 17.4, P=0.543). The liver disease status was more severe in Cook group than in EL group, but it did not show any significant difference after pregnancy termination between the two groups and the improvement rate also did not show any significant difference. Both treatments were safe and there was no significant difference in bleeding and cervical laceration adverse events between the two groups. Our study firstly compared double-balloon catheter and ethacridine lactate for the induction of labor in women with SLD during second trimester pregnancy.
[Mh] Termos MeSH primário: Aborto Induzido
Cateteres
Etacridina/administração & dosagem
Hepatopatias/fisiopatologia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Gravidez
Segundo Trimestre da Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1507
[Cu] Atualização por classe:171104
[Lr] Data última revisão:
171104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150213
[St] Status:MEDLINE
[do] DOI:10.1007/s11596-015-1401-x


  7 / 187 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24948048
[Au] Autor:Mei Q; Li X; Liu H; Zhou H
[Ad] Endereço:The Second People's Hospital of Yichang City, The Second People's Hospital of Three Gorges University, Yichang, China. Electronic address: 406632917@qq.com.
[Ti] Título:Effectiveness of mifepristone in combination with ethacridine lactate for second trimester pregnancy termination.
[So] Source:Eur J Obstet Gynecol Reprod Biol;178:12-5, 2014 Jul.
[Is] ISSN:1872-7654
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare the efficacy of mifepristone and ethacridine lactate with ethacridine lactate alone for second trimester pregnancy termination. STUDY DESIGN: Two hundred and seventy-six healthy women between 16 and 27 weeks of gestation, desiring a termination, were assigned at random into two groups. The study group consisted of 140 women who received an intra-amniotic injection of 100mg ethacridine lactate, followed by oral administration of 50mg mifepristone at 0, 12 and 24h (total dose of mifepristone 150mg). The control group consisted of 136 women who received an intra-amniotic injection of 100mg ethacridine lactate alone. The primary outcome measure was the induction-to-abortion interval. Secondary outcomes included blood loss in 24h, successful abortion rate, retained placental tissue rate, rate of uterine evacuation and cervical laceration. RESULTS: Induction-to-abortion interval, blood loss in 24h, rate of retained placental tissue and uterine evacuation were significantly less in the study group compared with the control group (p<0.001). Termination was successful in 140 of 140 women (100%) in the study group and 133 of 136 women (97.8%) in the control group. All women in the study group delivered within 72h, and three nulliparous women in the control group did not deliver within 72h. The cervical laceration rate was 0 and 1.47% (2/136) in the study group and the control group, respectively. No significant difference in the successful abortion rate (p=0.235) or the cervical laceration rate (p=0.242) was found between the two groups. CONCLUSION: Mifepristone in combination with ethacridine lactate may significantly improve the outcomes of second trimester pregnancy termination compared with ethacridine lactate alone, without increasing complications and side effects apart from nausea.
[Mh] Termos MeSH primário: Abortivos/administração & dosagem
Etacridina/administração & dosagem
Mifepristona/administração & dosagem
[Mh] Termos MeSH secundário: Aborto Induzido
Administração Intravaginal
Administração Oral
Adulto
China
Feminino
Seres Humanos
Gravidez
Segundo Trimestre da Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Abortifacient Agents); 320T6RNW1F (Mifepristone); WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1502
[Cu] Atualização por classe:140620
[Lr] Data última revisão:
140620
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140621
[St] Status:MEDLINE


  8 / 187 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23445335
[Au] Autor:Junka A; Bartoszewicz M; Smutnicka D; Secewicz A; Szymczyk P
[Ad] Endereço:Department of Microbiology, Medical University of Wroclaw, Wroclaw, Poland.
[Ti] Título:Efficacy of antiseptics containing povidone-iodine, octenidine dihydrochloride and ethacridine lactate against biofilm formed by Pseudomonas aeruginosa and Staphylococcus aureus measured with the novel biofilm-oriented antiseptics test.
[So] Source:Int Wound J;11(6):730-4, 2014 Dec.
[Is] ISSN:1742-481X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Increasing data suggesting that microorganisms in the biofilm form are among the leading agents of persistent infections of chronic wounds require the development of new approaches to treatment. The aim of this article was to compare the efficacy of three commonly used antiseptics using a biofilm-oriented approach. Biofilm-oriented antiseptics test (BOAT), the innovative method, allows to estimate, in a quick and reliable manner, the in vitro activity of working solutions of antiseptics in real contact times against bacteria in the biofilm form and to use the results in the selection of an appropriate antiseptic to treat local infections in the clinical practice.
[Mh] Termos MeSH primário: Anti-Infecciosos Locais/farmacologia
Biofilmes/efeitos dos fármacos
Etacridina/farmacologia
Povidona-Iodo/farmacologia
Pseudomonas aeruginosa/efeitos dos fármacos
Piridinas/farmacologia
Staphylococcus aureus/efeitos dos fármacos
[Mh] Termos MeSH secundário: Pseudomonas aeruginosa/fisiologia
Staphylococcus aureus/fisiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents, Local); 0 (Pyridines); 85H0HZU99M (Povidone-Iodine); OZE0372S5A (octenidine); WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130301
[St] Status:MEDLINE
[do] DOI:10.1111/iwj.12057


  9 / 187 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23841224
[Au] Autor:Fagerer SR; Nielsen S; Ibáñez A; Zenobi R
[Ad] Endereço:Department of Chemistry and Applied Biosciences, ETH Zurich, CH-8093 Zurich, Switzerland.
[Ti] Título:Matrix-assisted laser desorption/ionization matrices for negative mode metabolomics.
[So] Source:Eur J Mass Spectrom (Chichester);19(1):39-47, 2013.
[Is] ISSN:1469-0667
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Matrix-assisted laser desorption/ionization (MALDI) has been shown to be highly sensitive for analyzing low-mass compounds such as metabolites if the right matrix is used. 9-aminoacridine (9AA) is the most commonly employed matrix for negative mode MALDI-MS in metabolomics. However, matrix interferences and the strongly varying sensitivity for different metabolites make a search for alternative matrices desirable, in order to identify compounds with a different chemical background and/or favoring a different range of analytes. We tested the performance of a series of potential negative mode MALDI matrices with a mix of 29 metabolites containing amino acids, nucleotide phosphates and Krebs cycle intermediates. While ethacridine lactate was found to provide limits of detection (LODs) in the low femtomole range for nucleotide phosphates, amino acids and Krebs cycle intermediates in the low picomole range, 4-amino-2-methylquinoline showed LODs in the picomole range for most metabolites, but is capable of ionizing a broader range of analytes than both 9AA and ethacridine.
[Mh] Termos MeSH primário: Metabolômica/métodos
Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz/métodos
[Mh] Termos MeSH secundário: Aminacrina/química
Aminoácidos/análise
Aminoácidos/química
Aminoquinolinas/química
Etacridina/química
Limite de Detecção
Nucleotídeos/análise
Nucleotídeos/química
Quinaldinas/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (4-amino-2-methylquinoline); 0 (Amino Acids); 0 (Aminoquinolines); 0 (Nucleotides); 0 (Quinaldines); 78OY3Z0P7Z (Aminacrine); WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:160919
[Lr] Data última revisão:
160919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130712
[St] Status:MEDLINE


  10 / 187 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22803677
[Au] Autor:Shimazaki Y; Miki S
[Ad] Endereço:Department of Chemistry and Biology, Graduate School of Science and Engineering and Venture Business Laboratory, Ehime University , Matsuyama , Japan.
[Ti] Título:Analysis of enzyme activity regulation by non-denaturing electrophoresis and application of this regulation for enzyme reactor production.
[So] Source:J Enzyme Inhib Med Chem;28(5):894-9, 2013 Oct.
[Is] ISSN:1475-6374
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Non-denaturing electrophoresis can be used to screen enzymes that self-regulate their activities by using a combination of enzymes and their inhibitors. Furthermore, this technique can be applied to develop enzyme reactors that self-regulate their activities. After separation of proteins from mouse liver cytosol by non-denaturing isoelectric focusing, lactate dehydrogense (LDH) and esterase activities were qualitatively and quantitatively examined using a combination of two-dimensional electrophoresis (2-DE) and non-denaturing stacking gel electrophoresis. Activities of mouse liver-derived LDH and carboxylesterase were reversibly inhibited by oxamate and 6,9-diamino-2-ethoxyacridine (acrinol), respectively, in the stacking gels and recovered when the enzymes migrated towards the separation gels. After separation and immobilization of the enzymes, their activities were inhibited by inhibitors and recovered after inhibitor removal. These results indicate that non-denaturing electrophoresis can be applied to select enzymes that self-regulate their activities and subsequently aid in the development of enzyme reactors that can control the enzyme activities.
[Mh] Termos MeSH primário: Ativadores de Enzimas/metabolismo
Esterases/metabolismo
L-Lactato Desidrogenase/metabolismo
Eletroforese em Gel de Poliacrilamida Nativa
[Mh] Termos MeSH secundário: Animais
Citosol/enzimologia
Citosol/metabolismo
Relação Dose-Resposta a Droga
Eletroforese
Ativação Enzimática/efeitos dos fármacos
Inibidores Enzimáticos/química
Inibidores Enzimáticos/farmacologia
Esterases/antagonistas & inibidores
Esterases/isolamento & purificação
Etacridina/química
Etacridina/farmacologia
Focalização Isoelétrica
L-Lactato Desidrogenase/antagonistas & inibidores
L-Lactato Desidrogenase/isolamento & purificação
Fígado/enzimologia
Fígado/metabolismo
Camundongos
Ácido Oxâmico/química
Ácido Oxâmico/farmacologia
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Enzyme Activators); 0 (Enzyme Inhibitors); EC 1.1.1.27 (L-Lactate Dehydrogenase); EC 3.1.- (Esterases); QU60N5OPLG (Oxamic Acid); WIX85M1A6R (Ethacridine)
[Em] Mês de entrada:1404
[Cu] Atualização por classe:130911
[Lr] Data última revisão:
130911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120719
[St] Status:MEDLINE
[do] DOI:10.3109/14756366.2012.693918



página 1 de 19 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde